CCL2 and neoplasm: Treatment of tumor cell lines with a platinum-containing STAT3 inhibitor (CPA-7) or expression of dominant-negative STAT3 (STAT3β) splice variant resulted in increased secretion of chemoattractants, such as RANTES, IFN-γ-inducible protein (IP-10), MCP-1, MIP-2, and T cell activation (TCA)-3.